Patents by Inventor Philip J. Stephens
Philip J. Stephens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220412981Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g.Type: ApplicationFiled: March 4, 2022Publication date: December 29, 2022Inventors: David FABRIZIO, Garrett M. FRAMPTON, Priti HEGDE, Marcin KOWANETZ, David SHAMES, Philip J. STEPHENS, James Xin SUN, Roman YELENSKY, Wei ZOU
-
Publication number: 20220153861Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).Type: ApplicationFiled: February 2, 2022Publication date: May 19, 2022Inventors: Richard BOURGON, David FABRIZIO, Gregg FINE, Garrett M. FRAMPTON, Priti HEGDE, Sanjeev MARIATHASAN, Philip J. STEPHENS, James Xin SUN, Roman YELENSKY
-
Patent number: 11300570Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g.Type: GrantFiled: April 1, 2019Date of Patent: April 12, 2022Assignees: Genentech, Inc., Foundation Medicine, Inc.Inventors: David Fabrizio, Garrett M. Frampton, Priti Hegde, Marcin Kowanetz, David Shames, Philip J. Stephens, James Xin Sun, Roman Yelensky, Wei Zou
-
Patent number: 11279767Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).Type: GrantFiled: August 28, 2018Date of Patent: March 22, 2022Assignees: Genentech, Inc., Foundation Medicine, Inc.Inventors: Richard Bourgon, David Fabrizio, Gregg Fine, Garrett M. Frampton, Priti Hegde, Sanjeev Mariathasan, Philip J. Stephens, James Xin Sun, Roman Yelensky
-
Publication number: 20190219586Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g.Type: ApplicationFiled: April 1, 2019Publication date: July 18, 2019Inventors: David Fabrizio, Garrett M. Frampton, Priti Hegde, Marcin Kowanetz, David Shames, Philip J. Stephens, James Xin Sun, Roman Yelensky, Wei Zou
-
Publication number: 20180371099Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).Type: ApplicationFiled: August 28, 2018Publication date: December 27, 2018Inventors: Richard BOURGON, David FABRIZIO, Gregg FINE, Garrett M. FRAMPTON, Priti HEGDE, Sanjeev MARIATHASAN, Philip J. STEPHENS, James Xin SUN, Roman YELENSKY
-
Publication number: 20180363066Abstract: Methods of evaluating tumor mutational burden in a sample, e.g., a tumor sample or a sample derived from a tumor, from a subject, are disclosed.Type: ApplicationFiled: August 28, 2018Publication date: December 20, 2018Inventors: Zachary R. Chalmers, Caitlin F. Connelly, David Fabrizio, Garrett Michael Frampton, Priti Hegde, Marcin Kowanetz, Philip J. Stephens, James Xin Sun, Roman Yelensky
-
Publication number: 20140336943Abstract: Various embodiments provide interfaces to access genomic testing information and incorporate it into daily physician practice. In some embodiments, presentation of genomic alteration data is simplified and/or coupled with contextual applications. Volumes of genomic alterations and associated information (e.g., journal articles, clinical trial information, therapies, etc.) are analyzed and synthesized into actionable information items viewable on an alteration system. According to one embodiment, the system can be configured to focus practitioners on discrete portions of the alteration information on which they can act. According to other aspects, curated information is provided on the system to enable practitioners to make informed decisions regarding the implications of the presence of specific genomic alterations.Type: ApplicationFiled: January 3, 2014Publication date: November 13, 2014Applicant: FOUNDATION MEDICINE, INC.Inventors: Michael Pellini, Gary Palmer, Mary P. Lancelotta, Matthew J. Hawryluk, Philip J. Stephens
-
Patent number: 6261103Abstract: An interactive computer system for teaching laboratory-based sciences. According to one embodiment, the system includes a data acquisition module, an internet-based coursework database, and internet-based interactive software tools. Using the interactive software tools, an instructor can select academic course materials and related laboratory experiments from the coursework database. The instructor can create an Internet web page, which provides students with an interactive visual interface with the selected course materials and laboratories, along with various analysis tools. The data acquisition module is located at the site of an experimentation laboratory, and interfaces with laboratory equipment to capture data from selected experiments. Experimental data is transmitted in real-time to an internet-based storage location.Type: GrantFiled: April 15, 1999Date of Patent: July 17, 2001Assignee: CB Sciences, Inc.Inventors: Philip J. Stephens, Christopher J. Dufort, Clifford C. Bredenberg, Ashish More, William P. Mitchell